Terminated PHASE1 INTERVENTIONAL 2-arm NCT00003926

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

A Phase I Study of the Chemoprotectant Amifostine With Autologous Stem Cell Transplantation for High Risk or Relapsed Pediatric Solid Tumors and Brain Tumors

Sponsor: Masonic Cancer Center, University of Minnesota

Conditions Brain and Central Nervous System Tumors Childhood Germ Cell Tumor Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma

Interventions amifostine trihydrate busulfan filgrastim melphalan peripheral blood stem cell transplantation (PBSC) thiotepa

Updated 6 times since 2017 Last updated: Nov 27, 2017 Started: Nov 30, 1998 Primary completion: Aug 31, 2002 Completion: Aug 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Withdrawn due to slow accrual

Other terminated trials from Masonic Cancer Center, University of Minnesota

See all terminations from Masonic Cancer Center, University of Minnesota

Other Brain and Central Nervous System Tumors trials with similar outcome

Browse all Brain and Central Nervous System Tumors trials

Listed as NCT00003926, this PHASE1 trial focuses on Brain and Central Nervous System Tumors and Childhood Germ Cell Tumor and remains terminated or withdrawn. Sponsored by Masonic Cancer Center, University of Minnesota, it has been updated 6 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Nov 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Masonic Cancer Center, University of Minnesota

Data source: Masonic Cancer Center, University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States